


Bio-Energetic Sequencing: Commercializing the Solution to Biological Aging




The **\$1 Trillion** Opportunity to
Transform Human Healthspan

Aging is Not a Disease; It's a Systemic Failure Generating Every Major Disease.



Projected Growth, Global 65+ Population




Current approaches are reactive, expensive, and address symptoms, not the root cause.

We've Moved Aging From a Biological Mystery to a Solvable Engineering Problem.



The Bio-Energetic Sequencing Model: A **dependency-gated** protocol that systematically restores cellular maintenance. For the first time, we address the *root cause* in the *right order*.


Built on a Decade of Converging Breakthroughs in Geroscience



Underpinned by 74 peer-reviewed sources, foundational IP, and a framework for biomarker-based regulatory endpoints.

Competitors Are Targeting a Single Domino. We Control the Entire Cascade.

Competitors: The Silos



Single-Target

Unsequenced

Palliative

Our Approach: The System




Systemic

Sequenced


Regenerative

Single-target interventions fail because they ignore dependencies. You can't regenerate tissue (Phase 4) while it's suppressed by senescent cells (Phase 3). You can't clear cellular damage (Phase 2) without sufficient energy (Phase 1). **Our sequence is our moat.**


A Multi-Channel Healthspan Ecosystem Built on a Single Core Platform



Projected 5-Year Revenue Mix



A Disciplined, Phased Rollout to Capture the High-Value Market First.



0-18 Months

Establish the Beachhead

Prove unit economics with high-net-worth individuals, generating a premium brand halo.

18-36 Months

Scale the Model

Achieve capital-efficient growth and reach profitability.

36-60 Months

Global Platform Leadership

Achieve unicorn valuation and establish market dominance.

0 Months

18 Months

36 Months

60 Months

Strong Market Signals Indicate The World is Ready



High-Value Demand

Early adopter interest from HNWIs, professional athletes, and tech executives, exemplified by figures like biohacker Ben Greenfield.



Healthcare System Pull

Inbound interest from concierge medicine groups seeking preventative, high-value solutions.



Regulatory Precedent

Clear pathway for biomarker-based approvals, following precedents like the FDA TAME trial for metformin, which targets aging as a treatable condition.




World-Class Advisory

Assembled a strategic advisory board of leading geroscience researchers from institutions like the Buck Institute and veteran healthcare executives.

A High-Margin, Capital-Efficient Model with Strong Unit Economics


5-Year Revenue Growth




Key Unit Economics

	Customer Lifetime Value (LTV)	\$50,000 - \$200,000 (5-yr)
	Gross Margin	70%+
	Customer Acquisition Cost (CAC) Payback	< 12 Months

Path to Profitability



\$20M Series A to Execute Phase 1 and Unlock a 10x Valuation Step-Up.



Key Milestones Unlocked



World-Class Science Meets Proven Execution.

Scientific & Medical Leadership



Jane Doe, PhD
Chief Scientific Officer
Former Researcher,
Buck Institute



John Smith, MD
Chief Medical Officer
Contributor to Information
Theory of Aging research



Dr. Sarah Lee, PhD
Head of Research
Leading expert in
Epigenetic Clocks




Dr. Mark Davis, MD
Lead Clinician
Board-certified in
Longevity Medicine

Business & Operations Leadership



Emily Chen
Chief Executive Officer
Scaled [XYZ Concierge
Clinic] to 50 locations



David Rodriguez
Chief Operating Officer
Ex-Google Health, led
commercialization



Anna Kim, MBA
Chief Financial Officer
Experienced in
Healthcare Investment



Michael Brown
Chief Marketing Officer
Former VP at [Major
Healthcare Brand]

The Ground Floor of the Healthspan Revolution.

Seeking **\$20M Series A** to become the category-defining leader in **engineered healthspan**.

- **Massive, Untapped Market:** Addressing the \$3T+ root cause of all major chronic diseases.
- **Defensible Scientific Moat:** A unique, dependency-gated systems model that is scientifically superior to all single-target approaches.
- **Clear Path to Profitability:** A high-margin, multi-channel business model with proven unit economics.
- **World-Class Team:** The right blend of scientific vision and operational excellence to execute the plan.

Exit Opportunities: IPO, Strategic Acquisition (Big Pharma/Biotech).

Contact: [Name], [Email], [Phone Number].